# Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

> **NCT06694740** · PHASE2,PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 170 (estimated)

## Conditions studied

- Post-aggressive Immunosuppression
- Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6
- Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C

## Interventions

- **DRUG:** Interferon Gamma 1-b
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06694740
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-12
- **Primary completion:** 2028-02
- **Final completion:** 2028-04
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06694740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06694740, "Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06694740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*